Related Experiment Video
Updated: Jun 20, 2026
09:30
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
CYP2D6: novel genomic structures and alleles
Whitney E Kramer1, Denise L Walker, Dennis J O'Kane
1Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
Pharmacogenetics and Genomics
|September 11, 2009
Summary
This study characterizes novel genomic structures of the CYP2D6 gene, revealing insights into complex rearrangements. Understanding these CYP2D6 variations improves clinical genotyping accuracy.
Area of Science:
- Pharmacogenomics
- Molecular genetics
Background:
- The CYP2D6 gene is highly polymorphic, with deletions, duplications, and recombination events involving CYP2D7.
- These variations can interfere with current clinical genotyping platforms.
Purpose of the Study:
- To elucidate the genomic structure of CYP2D6 recombinants affecting clinical genotyping.
- To identify novel CYP2D6 alleles and their structures.
Main Methods:
- Analysis of clinical samples with rare CYP2D6 alleles, duplications, and ambiguous results.
- Utilized long-range PCR, fragment analysis, allele-specific primer extension, and DNA sequencing.
Main Results:
- Characterized novel CYP2D6 alleles and their unique genomic structures.
- Identified identical tandem alleles in most CYP2D6 gene duplications/multiplications (49/50 samples).
Conclusions:
- Several new CYP2D6 alleles and genomic structures were identified, aiding CYP2D6 genotyping.
- Recombination events causing CYP2D6 duplications/multiplications may involve non-meiotic crossover mechanisms.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
02:26Comparing Copy Number Variations and SNPs
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...